Personalising glaucoma surgery: The role of MIGSJune 22nd 2021
Minimally invasive glaucoma surgery (MIGS) is appealing to glaucoma patients and surgeons; however, it should not be adopted without further high-quality research and careful reporting. Selection of the appropriate treatment for individual patients must be evidence based.
Using pivotal study data to guide glaucoma patient management decisionsJune 9th 2021
Two randomised controlled trials, EMGT and UKGTS, have examined the factors affecting the risk of glaucoma progression. Global target IOPs are not the best option for all patients.
Study examines pairing phacoemulsification with implantation of stentsApril 26th 2021
A cost-utility analysis found that concurrent phacoemulsification and minimally invasive glaucoma surgery using trabecular microbypass stents is cost-effective for treating mild to moderate open-angle glaucoma, compared with cataract surgery alone.
Precision management to revolutionise glaucoma diagnosis and treatmentMarch 26th 2021
Artificial intelligence and genetic testing are expected to facilitate choosing the best treatment for each unique glaucoma patient within the next decade. This will not only lead to the best outcomes for individuals but will also spare them the costs and side effects of suboptimal treatments.
Is low vitamin D a risk factor for primary open angle glaucoma?
Evidence for a connection between low vitamin D levels and glaucoma is increasing but the link remains speculative and no causal connection has been demonstrated.
Considering the best surgical approach in angle closure patientsMarch 8th 2021
Intraocular drainage surgery in angle closure remains experimental and investigators are collecting data regarding its efficacy as well as adverse effects.